Some stage II CRC patients with risk factors and all stage III CRC patients are routinely assigned to receive chemotherapy regimens, so the association between PPM1H expression and the efficiency of chemotherapy was explored in this study. This evidence concerns the gene PPM1H and colorectal carcinoma.